
FDA Approves Genentech’s Vabysmo PFS for Vision Loss Causes
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Vabysmo® (faricimab-svoa) 6.0 mg single-dose prefilled syringe (PFS) for treating wet age-related macular degeneration (AMD), diabetic…












